POZ - Treatment News : New Wave of Transmitted Drug Resistance Predicted for San Francisco

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » January 2010

What's That Mean?
(just double-click it!)

NEW! If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


email print

January 15, 2010

New Wave of Transmitted Drug Resistance Predicted for San Francisco

The number of new HIV infections with virus resistant to HIV drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTIs) could rise significantly in San Francisco and become a self-sustaining epidemic, according to a study published online January 14 in the journal Science and reported by Bloomberg News. The authors also fear that an upswing in transmitted drug-resistant virus could imperil efforts to test and treat nearly everyone living with HIV in developing countries.

Transmitted drug resistance (TDR) is an ever-present concern for scientists, physicians and people with HIV. When people with drug-resistant HIV pass their virus to others, those newly infected people have fewer treatment options.

Thus far, TDR has remained fairly stable at about 14 percent or less of new infections in many Western countries. About 75 percent of TDR HIV cases in San Francisco involve virus resistant to NNRTIs, such as Sustiva (efavirenz) and Viramune (nevirapine).

To determine whether TDR is likely to remain stable or to grow in San Francisco, a group of biomedical mathematicians led by Sally Blower, PhD, from the University of California in Los Angeles, devised a mathematical model of TDR. This model took into account current trends, as well as the likely infectiousness of different strains of drug-resistant virus.

Blower’s team found that although most TDR strains are not likely to rise significantly, there is lingering concern with transmitted NNRTI-resistant strains. “If only 70 percent [of people on NNRTIs] are virally suppressed, NNRTI-resistance could increase by more than 30 percent,” Blower explained.

“Our results have shown that effective treatments have prevented TDR from increasing to greater than 15 percent in San Francisco,” she continued. “However, our modeling shows the network is continuing to evolve. Disturbingly, we found the majority of the resistant strains currently being transmitted in this city are capable of causing self-sustaining epidemics…. We predict a wave of NNRTI-resistant strains will emerge over the next five years in San Francisco due to transmission from untreated individuals.”

The model also has Blower and her colleagues fearing that the potential wave of new TDR in San Francisco could have dire implications for the developing world—where the choice of second-line regimens is extremely limited. Blower explained that resistance is most likely to develop against NNRTIs, compared with other current HIV drugs, and that NNRTIs are used almost universally as first-line treatment in the developing world.

Some experts have proposed a massive “test and treat” campaign to test most people for HIV and provide ARV treatment as a way to increase survival among people with HIV and prevent new infections.

Blower, however, cautions against this approach. “Universal test and treat is just a recipe for disaster,” she told Bloomberg News. “Our modeling is saying the drug resistant strains that you will generate from this kind of strategy are ones that will be very strong, transmissible, and therefore you will get an awful lot of problems.”

Search: Transmitted drug resistance, TDR, transmission, resistance, NNRTI, Sustiva, efavirenz, Viramune, nevirapine, San Francisco, test and treat, Sally Blower


Scroll down to comment on this story.

email print

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

  comments 1 - 1 (of 1 total)    

Chad, San Francisco, 2010-01-20 16:49:02
So the lesser of two evils is not discovering the true scope of the disease and providing universal access to care because it would lead to more TDR? The virus has and will mutate no matter what we do. Might as well care for those we can and work out another treatment for the 30%.

comments 1 - 1 (of 1 total)    


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar
Starting Treatment
Quilt in the Capital
POZ Army


    dulce_angelita
    Bronx
    New York


    sequoiamv
    San Jose
    California


    Fae894
    Coral Springs
    Florida


    RayOctober
    Atlanta
    Georgia
Click here to join POZ Personals!
Talk to Us
Poll
Do you support rapid in-home HIV testing?
Yes
No

Survey
Health 2.0

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.